Oct 2017: Salipro® for functional studies of a GPCR with NMR. Half-life of GPCR in Salipro® extended from 1.5 to 30 days. Check out the latest paper on our technology by Nietlispach et al: http://pubs.acs.org/doi/10.1021/jacs.7b06730
Oct 2017: Salipro Biotech is presenting at the Genesis Drug Discovery meeting in Frankfurt (11.-12.10.2017)
Sept 2017: Meet Salipro Biotech at the Nordic Life Science Days 2017 in Malmö (12.-14.09.2017)
Jan 2017: We're growing and moving to new premises in central Stockholm. With more lab space and offices, we're located at the Greenhouse Labs at the Royal Institute of Technology in Stockholm. Location
Sept 2016: Prof Poul Nissen joins the advisory board.
Aug 2016: Salipro Biotech AB successfully completes a first feasibility study with AstraZeneca. Stefan Geschwindner, Principal Scientist, AstraZeneca R&D Gothenburg: “We have been impressed by the fact that Salipro Biotech is able to work both with detergent-solubilised material as well as with crude cell-membranes and furthermore demonstrated good feasibility to generate non-aggregated membrane proteins in a detergent-free form. This forms an excellent basis for the next steps that will include both structural and biophysical work.”
Aug 2016: Håkan Garpenstrand joins the advisory board for business development and corporate strategy.
May 2016: Salipro Biotech AB enters into study agreement with AstraZeneca.